Advertisement
Research Article Free access | 10.1172/JCI117493
Department of Cardiovascular Pharmacology, Gensia Inc., San Diego, California 92121.
Find articles by Bullough, D. in: JCI | PubMed | Google Scholar
Department of Cardiovascular Pharmacology, Gensia Inc., San Diego, California 92121.
Find articles by Zhang, C. in: JCI | PubMed | Google Scholar
Department of Cardiovascular Pharmacology, Gensia Inc., San Diego, California 92121.
Find articles by Montag, A. in: JCI | PubMed | Google Scholar
Department of Cardiovascular Pharmacology, Gensia Inc., San Diego, California 92121.
Find articles by Mullane, K. in: JCI | PubMed | Google Scholar
Department of Cardiovascular Pharmacology, Gensia Inc., San Diego, California 92121.
Find articles by Young, M. in: JCI | PubMed | Google Scholar
Published October 1, 1994 - More info
Inhibition of platelet aggregation by acadesine was evaluated both in vitro and ex vivo in human whole blood using impedance aggregometry, as well as in vivo in a canine model of platelet-dependent cyclic coronary flow reductions. In vitro, incubation of acadesine in whole blood inhibited ADP-induced platelet aggregation by 50% at 240 +/- 60 microM. Inhibition of platelet aggregation was time dependent and was prevented by the adenosine kinase inhibitor, 5'-deoxy 5-iodotubercidin, which blocked conversion of acadesine to its 5'-monophosphate, ZMP, and by adenosine deaminase. Acadesine elevated platelet cAMP in whole blood, which was also prevented by adenosine deaminase. In contrast, acadesine had no effect on ADP-induced platelet aggregation or platelet cAMP levels in platelet-rich plasma, but inhibition of aggregation was restored when isolated erythrocytes were incubated with acadesine before reconstitution with platelet-rich plasma. Acadesine (100 mg/kg i.v.) administered to human subjects also inhibited platelet aggregation ex vivo in whole blood. In the canine Folts model of platelet thrombosis, acadesine (0.5 mg/kg per min, i.v.) abolished coronary flow reductions, and this activity was prevented by pretreatment with the adenosine receptor antagonist, 8-sulphophenyltheophylline. These results demonstrate that acadesine exhibits antiplatelet activity in vitro, ex vivo, and in vivo through an adenosine-dependent mechanism. Moreover, the in vitro studies indicate that inhibition of platelet aggregation requires the presence of erythrocytes and metabolism of acadesine to acadesine monophosphate (ZMP).